Furthermore, consistent with the correlations observed in this analysis, CD44 has been associated with cellular mobility and GBM aggressiveness23 and PTEN loss has been associated poor outcomes in recurrent GBM treated with neoadjuvant anti-PD111. This evidence concerns the gene CD44 and glioblastoma.